lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry

Background Patient demographics and shared decision making might influence the choice of adjuvant therapy for stage III melanoma. Objective To identify factors for treatment selection of patients diagnosed with stage III melanoma to better understand current treatment decisions and improve further treatment counseling. Patients and Methods Data from 2007 patients diagnosed with stage III melanoma, between December 2018 and 2021, sourced from the Dutch Cancer Registry, were analyzed. Results Among the cohort, 48.7% received no therapy, 45.8% received checkpoint inhibition, and 5.5% received targeted therapy (TT). Patients foregoing therapy were significantly older [67.0 years (range 53.0–77.0) vs. 62.0 year (range 52.0–72.0)], had poorer performance scores (PS), and higher Charlson Comorbidity Index scores compared to those receiving therapy ( p